OakChart

HCW Biologics Inc

HCWBHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 10:53 AM ET

0.9700+0.0300 (3.19%)
2026-11-11 16:58 CET
Market cap
2.10 USD m
Revenue, TTM
6.72 USD m
Net income, TTM
-22.14 USD m
Free cash flow, TTM
-12.14 USD m
EPS diluted, TTM
-28.42
P/E
-
Compare

Price

HCWB against its 20, 50 and 200-day averages
2050200beatmiss
0.0010.0020.0032.9M65.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HCWBclose 0.9720-day 1.1250-day 1.62200-day 3.840.9752w high

95.9% under the 52-week high of 23.94 on 20 May 2026. 52-week low 0.94 on 10 Nov 2026. Last 15 sessions, 36.2% high to low

Profile

HCWB
52-week range, 0% of the way up
0.9423.94

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

Employees35
IPOJul 20, 2021
Beta2.28
ATR, 14d0.12
Rel volume0.03
Short float2.40%
Insider own8.37%
Inst own5.17%

Snapshot

6 groups

Valuation

Index-
Market Cap2.17M
Enterprise Value7.99M
Income-22.14M
Sales6.72M
Book/sh4.59
Cash/sh0.33
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees35
IPOJul 20, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S0.32
P/B0.21
P/C2.93
P/FCF-
EV/EBITDA-
EV/Sales1.19
Quick Ratio0.06
Current Ratio0.06
Debt/Eq0.88
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-28.42
EPS next Y-1.05
EPS next Q-1.35
EPS this Y92.60%
EPS next Y77.75%
EPS next 5Y77.46%
EPS past 3/5Y13.87% -6.63%
Sales past 3/5Y-79.94% -57.90%
EPS Y/Y TTM70.52%
Sales Y/Y TTM707.02%
EPS Q/Q71.57%
Sales Q/Q1969.74%
EarningsAug 14 BMO
EPS/Sales Surpr.-484.85% -

Ownership

Insider Own8.37%
Insider Trans184.47%
Inst Own5.17%
Inst Trans-2.81%
ROA-79.52%
ROE-600.31%
ROIC-298.06%
Gross Margin86.99%
Oper. Margin-90.06%
Profit Margin-329.38%
SMA20-13.14%
SMA50-40.11%
SMA200-74.76%
Trades-

Technical

Shs Outstand2.24M
Shs Float2.05M
Short Float2.40%
Short Ratio0.12
Short Interest0.05M
52W High23.94 -95.95%
52W Low0.94 3.19%
Volatility7.45% 8.20%
ATR (14)0.12
RSI (14)30.12
Beta2.28
Rel Volume0.03
Avg Volume398.66K
Volume3,629

Performance

Perf Week-10.19%
Perf Month-23.02%
Perf Quarter-66.84%
Perf Half Y-53.73%
Perf YTD-83.34%
Perf Year-94.29%
Perf 3Y-99.71%
Perf 5Y-99.86%
Perf 10Y-
Recom1.00
Target Price8.00
Prev Close0.94
Price0.97
Change %3.19%

Peers

Mkt cap
TickerCompanyMkt cap
GTBPGT Biopharma Inc8.22M
HOWLWerewolf Therapeutics Inc47.63M
XLOXilio Therapeutics Inc58.43M
CUECue Biopharma Inc142.45M
IMNNImunon Inc4.43M
NKTRNektar Therapeutics1.31B
INMBINmune Bio Inc34.67M
AIMAIM ImmunoTech Inc5.90M
STTKShattuck Labs Inc509.73M
INKTMiNK Therapeutics Inc51.90M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Wong Hing CChief Executive OfficerJul 29 '26Buy2.5823,21059,998125,845Jul 31 04:10 PM
Flowers LeeSVP of Business DevelopmentJul 29 '26Buy2.587,73619,9988,691Jul 31 04:06 PM
GARRETT SCOTT TDirectorJul 29 '26Buy2.587,73619,99841,644Jul 31 04:02 PM
Wong Hing CChief Executive OfficerMay 22 '26Buy1.41113,879160,000615,790May 27 07:26 PM
GARRETT SCOTT TDirectorMay 22 '26Buy1.41177,936250,000203,441May 27 07:25 PM
Byam RebeccaChief Financial OfficerMay 22 '26Buy1.4114,23520,00057,245May 27 07:23 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 206
  • HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer (GlobeNewswire)
  • HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company's Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer's 41st Annual Meeting (GlobeNewswire)
  • HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing (GlobeNewswire)
  • HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors (GlobeNewswire)
  • HCW Biologics Announces Pricing of $1.5 Million Private Placement (GlobeNewswire) +19.88%
  • Loading…
  • HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent (InvestorsHub) -14.63%
  • HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells (GlobeNewswire)
  • HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment (GlobeNewswire)
  • HCW Biologics' TGF-ß Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells (GlobeNewswire) +12.55%
  • HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results (GlobeNewswire) -8.38%
  • HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering (GlobeNewswire)
  • HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 (GlobeNewswire) -13.90%
  • HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter (GlobeNewswire) -5.06%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-11.580-1.980-3.9300.14-1
2026Q12026-05-142.220-2.6401.3896.53-1
2025Q42026-03-31-6.120-5.040-6.1450.01-1
2025Q32025-11-14-24.7809.480-12.0910.097.001
2025Q22025-08-18-40.74010.800-40.7220.007.001
2025Q12025-05-15-12.000--11.8010.01--
2024Q42025-03-28-19.20021.600-19.1380.087.001
2024Q32024-11-14-24.000-31.200-24.7610.43-1
2024Q22024-08-20-43.200-43.200-96.9580.62-1
2024Q12024-05-15-48.000--48.1510.61--
2023Q42024-04-01-72.000-34.800-71.2101.320.902
2023Q32023-11-14-33.600-31.200-32.9900.850.602
2023Q22023-08-11-28.800-36.000-28.7660.620.003
2023Q12023-05-09-33.600-33.600-33.9140.042.302
2022Q42023-03-28-36.000-36.792-36.2641.340.003
2022Q32022-11-07-26.400-31.200-26.2151.80-2

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-171.6-177.6-86.3060.000.00
2022FY-100.8-101.59-99.8306.725.39
2023FY-168-130.8-166.962.841.96
2024FY-184.8-136.8-185.752.579.17
2025FY-63.780-31.380-31.3800.050.03
2026FY--4.720--6.68
2027FY--1.050---
2028FY--0.730---
2029FY--0.580---
2030FY--0.620---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3R2026-10-01101-1.35-1.35-1.35
2026Q3R2026-08-14100-1.08-1.08-1.08
2026Q3R2026-08-11100-1.08-1.08-1.08
2026Q3R2026-05-28110-1.08-1.08-1.08
2026Q3R2026-05-18100-1.26-1.26-1.26
2026Q3R2026-05-15110-1.26-1.26-1.26
2026Q3R2026-04-01110-1.26-1.26-1.26
2026Q3R2026-03-04110-1.26-1.26-1.26
2026Q3R2025-12-19110-1.56-1.56-1.56
2026Q3R2025-11-17100-5.52-5.52-5.52
2026Q3R2025-11-11110-5.52-5.52-5.52
2026Q3R2025-11-10110-5.52-5.52-5.52
2026Q3R2025-11-09110-5.52-5.52-5.52
2026Q3R2025-11-08110-5.52-5.52-5.52

Estimate history

EPS, annual-50.894-46.26-86.306-99.83-166.956-185.748-63.78-28.4244
Period2019202020212022202320242025TTM
EPS, quarterly-96.958-24.761-19.138-11.801-40.722-12.091-6.1451.389-11.577
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual04.106.7222.8422.5670.0546.72
Period2019202020212022202320242025TTM
Sales, quarterly0.6190.4260.3950.0050.0070.0160.0276.5430.136
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.1530.1530.1490.1490.150.1860.5471.618
Period2019202020212022202320242025MRQ
Shares, quarterly0.1580.1580.1860.1870.3580.4370.5471.1221.618
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue6.720.052.572.846.720.004.100.00
Cost of Goods Sold Incl. D&A0.871.092.793.424.730.540.570.42
Gross Profit5.85-1.03-0.22-0.572.00-0.543.53-0.42
Selling, General and Administrative Excl. Other11.7012.1012.0425.1417.0812.829.356.94
Research and Development4.925.176.007.138.907.826.925.14
Other Operating Expense0.200.000.000.000.000.000.000.00
Operating Income-6.05-13.13-12.27-25.72-15.08-13.37-5.82-7.37
Interest Expense0.550.850.630.280.130.00-0.00
Unusual Expense-1.57-6.2117.210.000.00-0.570.000.00
Net Income Before Taxes-5.25-7.96-30.02-24.99-14.90-12.86-5.80-7.29
Income Taxes0.330.000.000.000.000.000.000.00
Consolidated Net Income-22.14-22.30-30.02-24.99-14.90-12.86-5.80-7.29
Net Income From Continuing Operations-22.14-22.30-30.02-24.99-14.90-12.86-5.80-7.29
Net Income-22.14-22.30-30.02-24.99-14.90-12.86-7.07-7.78
EPS (Recurring)-17.50-76.22-111.21-166.96-99.83-88.97-46.26-50.89
EPS (Basic, Before Extraordinaries)-28.42-63.78-185.75-166.96-99.83-86.31-46.26-50.89
EPS (Diluted)-28.42-63.78-185.75-166.96-99.83-86.31-46.26-50.89
EBITDA-5.45-12.09-11.08-24.58-14.49-12.82-5.25-6.94
Non-Operating Income (Expense)-0.22-0.200.091.010.30-0.060.020.07
Other After Tax Adjustments-12.370.000.000.000.000.000.000.00
Stock Option Compensation Expense0.220.771.011.001.120.360.020.00
Price To Sales Ratio0.9937.546.7415.4910.20---
Gross Margin86.99-1,900.95-8.77-20.2329.70-86.03-
Operating Margin-90.06-24,216.92-478.00-904.96-224.32--142.07-
Net Margin-329.38-41,117.24-1,169.70-879.52-221.67--172.54-
Shares Outstanding1.620.550.190.150.150.150.150.15
Market Capitalization2.102.1019.8744.0168.6282.9886.10-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.146.540.030.020.010.010.390.43
Cost of Goods Sold Incl. D&A0.360.150.180.190.300.421.000.47
Gross Profit-0.226.39-0.15-0.17-0.29-0.42-0.60-0.04
Selling, General and Administrative Excl. Other2.952.952.693.123.033.292.412.70
Research and Development1.131.171.331.290.991.120.961.13
Other Operating Expense0.000.200.000.000.000.000.000.00
Operating Income-3.173.24-2.84-3.29-3.32-3.71-3.01-2.74
Interest Expense0.100.110.210.130.230.260.250.22
Unusual Expense1.96-0.66-3.840.97-1.61-1.740.150.95
Net Income Before Taxes-5.223.800.72-4.55-1.93-2.20-3.37-3.90
Income Taxes0.000.330.000.000.000.000.000.00
Consolidated Net Income-15.371.26-3.47-4.55-12.08-2.20-3.37-3.90
Net Income From Continuing Operations-15.371.26-3.47-4.55-12.08-2.20-3.37-3.90
Net Income-15.371.26-3.47-4.55-12.08-2.20-3.37-3.90
EPS (Recurring)-10.540.88-10.91-10.28-44.51-18.34-18.55-20.54
EPS (Basic, Before Extraordinaries)-11.581.39-6.15-12.09-40.72-11.80-19.14-24.76
EPS (Diluted)-11.581.39-6.15-12.09-40.72-11.80-19.14-24.76
EBITDA-3.043.38-2.68-3.11-3.03-3.29-2.33-2.61
Non-Operating Income (Expense)0.010.01-0.07-0.170.020.020.030.01
Other After Tax Adjustments-10.15-2.220.000.00-10.150.000.000.00
Stock Option Compensation Expense0.000.010.010.210.280.280.290.23
Price To Sales Ratio0.990.3060.5719.818.478.727.355.84
Gross Margin-163.0097.66-561.05-1,094.35-4,436.73-8,252.66-152.87-10.12
Operating Margin-2,336.5549.56-10,520.87-21,056.77-50,710.46-73,154.89-762.61-642.74
Net Margin-11,340.3419.19-12,832.14-29,183.24-184,450.82-43,373.64-854.42-915.12
Shares Outstanding1.621.120.550.440.360.190.190.16
Market Capitalization2.102.423.189.708.5112.6819.8720.40

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments1.954.673.6032.0636.718.467.36
Short Term Receivables0.030.581.540.420.132.500.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.300.441.271.593.631.190.67
Total Current Assets2.285.706.4034.0740.4812.158.03
Net Property, Plant & Equipment20.8822.9120.4510.801.121.622.00
Total Investments and Advances1.331.601.601.6011.521.600.00
Other Assets0.030.030.060.330.390.030.03
Total Assets24.5230.2428.5146.8153.5115.4010.07
Short Term Debt Incl. Current Port. of LT Debt6.816.310.150.000.000.570.00
Accounts Payable13.1422.336.171.230.220.160.39
Other Current Liabilities1.110.982.431.732.100.280.67
Total Current Liabilities21.0629.638.752.962.321.001.07
Long Term Debt0.007.386.306.420.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.690.000.000.000.000.000.00
Total Liabilities21.7637.0115.059.382.321.001.07
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0031.1218.68
Common Equity2.76-6.7713.4637.4351.19-16.72-9.68
Total Shareholders Equity2.76-6.7713.4637.4351.1914.409.00
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity2.76-6.7713.4637.4351.1914.409.00
Total Liabilities & Stockholders Equity24.5230.2428.5146.8153.5115.4010.07
Book Value Per Share5.06-36.4889.68250.38343.50-109.33-63.28
Tangible Book Value Per Share5.06-36.4889.68250.38343.50-109.33-63.28
Full-Time Employees3536454444--
Price to Book Ratio0.20-2.931.841.611.621.59-
Return on Assets-81.45-102.21-66.37-29.71-37.33-45.57-
Return on Equity--897.37-98.23-33.63-39.22-49.60-
Return on Invested Capital-806.53-4,940.62-126.45-33.98-25.13-40.30-81.03
Quick Ratio0.110.190.7311.5217.4412.147.53
Current Ratio0.110.190.7311.5217.4412.147.53

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-5.58-7.96-30.02-24.99-14.90-12.86-5.80-7.29
Depreciation0.601.041.181.140.590.540.600.42
Other Funds (Non Cash)-4.71-3.691.015.991.44-0.110.020.00
Funds from Operations-9.69-10.61-27.83-17.87-12.87-12.43-5.18-6.87
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-2.44-2.7813.60-4.642.491.46-5.250.10
Cash from Operating Activities-12.14-13.39-14.23-22.51-10.39-10.98-10.43-6.77
Capital Expenditures0.000.00-0.26-6.20-10.28-0.05-0.19-1.46
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.0010.0024.98-34.970.000.00
Purchase of Investments0.000.000.000.000.00-34.970.000.00
Sale Or Maturity of Investments0.000.000.0010.0024.980.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.263.8014.71-35.02-0.19-1.46
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock10.8010.658.780.02-0.1749.2711.1513.45
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.8010.658.780.02-0.1749.2711.1513.45
Proceedsfrom Stock Options5.8410.658.780.02-0.1749.2711.1513.45
Issuance or Reduction of Debt, Net-0.230.026.79-0.046.450.000.560.00
Change in Long Term Debt-0.230.156.910.006.450.000.000.00
Issuance of Long Term Debt0.000.156.910.006.450.000.000.00
Reduction of Long Term Debt-0.230.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities10.4410.6715.57-0.016.2749.2711.7213.45
Net Change in Cash-1.70-2.721.08-18.7310.603.271.105.22
Free Cash Flow-12.14-13.39-14.49-28.72-20.66-11.02-10.62-8.23
Preferred Dividends (Cash Flow)-0.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.741.231.951.102.441.11
Short Term Receivables0.020.070.030.030.020.09
Inventories0.000.000.000.000.000.00
Other Current Assets0.380.420.300.460.440.70
Total Current Assets1.141.722.281.592.901.89
Net Property, Plant & Equipment20.7520.7720.8822.5022.6422.76
Total Investments and Advances4.854.831.331.333.351.60
Other Assets0.030.030.030.030.030.03
Total Assets26.7727.3424.5225.4528.9126.29
Short Term Debt Incl. Current Port. of LT Debt6.566.586.816.816.426.23
Accounts Payable10.6111.7913.1418.9719.3519.73
Other Current Liabilities1.481.601.111.081.071.17
Total Current Liabilities18.6519.9621.0626.8626.8527.14
Long Term Debt0.000.000.000.692.127.71
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.691.620.690.000.000.00
Total Liabilities19.3421.5821.7627.5528.9634.85
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity7.435.762.76-2.11-0.05-8.56
Total Shareholders Equity7.435.762.76-2.11-0.05-8.56
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity7.435.762.76-2.11-0.05-8.56
Total Liabilities & Stockholders Equity26.7727.3424.5225.4528.9126.29
Book Value Per Share4.595.135.06-4.82-0.15-45.73
Tangible Book Value Per Share4.595.135.06-4.82-0.15-45.73
Full-Time Employees--35---
Price to Book Ratio0.200.421.15-4.60-163.76-1.48
Return on Assets-79.52-70.29-81.45-85.40-77.35-87.29
Return on Equity-600.31-----27,725.80
Return on Invested Capital-206.9821.79-125.36--585.48-
Quick Ratio0.060.090.110.060.110.07
Current Ratio0.060.090.110.060.110.07

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-5.223.470.72-4.55-1.93-2.20
Depreciation0.130.140.160.170.290.42
Other Funds (Non Cash)1.96-4.16-3.871.35-1.600.43
Funds from Operations-3.13-0.54-2.99-3.03-3.24-1.35
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.84-1.03-0.36-0.21-0.04-2.16
Cash from Operating Activities-3.97-1.58-3.36-3.24-3.28-3.51
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.511.114.241.934.49-0.02
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.511.114.241.934.49-0.02
Proceedsfrom Stock Options0.06-0.394.241.934.49-0.02
Issuance or Reduction of Debt, Net-0.03-0.260.09-0.030.12-0.03
Change in Long Term Debt-0.03-0.260.09-0.030.12-0.03
Issuance of Long Term Debt0.000.000.000.000.150.00
Reduction of Long Term Debt-0.03-0.260.09-0.03-0.03-0.03
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.480.854.211.904.61-0.05
Net Change in Cash-0.49-0.720.86-1.341.33-3.57
Free Cash Flow-3.97-1.58-3.36-3.24-3.28-3.51

Revenue breakdown

Pharmaceutical Preparations2024: 2.57M 2025: 54.23K
United States2024: 2.57M 2025: 54.23K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.40%0.0M2.1M403.19K
2026-10-151.84%0.0M2.1M405.73K
2026-09-303.03%0.1M2.0M377.38K
2026-09-150.46%0.0M2.0M180.84K
2026-08-312.11%0.0M1.6M142.44K
2026-08-140.89%0.0M1.6M1.93M
2026-07-311.49%0.0M1.4M2.02M
2026-07-152.07%0.0M1.5M2.14M
2026-06-303.00%0.0M1.4M2.12M
2026-06-154.78%0.0M1.0M3.35M
2026-05-299.83%0.1M0.7M3.37M
2026-05-1575.39%0.6M0.9M2.59M
2026-04-3011.19%0.1M0.9M1.47M
2026-04-152.56%0.0M0.9M1.40M
2026-03-312.00%0.0M0.9M1.38M
2026-03-130.91%0.0M0.8M16.67K
2026-02-271.22%0.0M0.8M14.90K
2026-02-130.88%0.0M0.4M17.26K
2026-01-302.18%0.0M0.4M14.78K
2026-01-150.86%0.0M0.4M13.19K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-10-09EFFECTEffectiveness filing by commission orderSEC
2026-10-08DNotice of sales of securities on Form D (Regulation D)SEC
2026-10-02S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-10-01DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-01SEC
2026-09-248-KCurrent report2026-09-23SEC
2026-09-108-KCurrent report2026-09-09SEC
2026-09-09PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-088-KCurrent report2026-09-04SEC
2026-09-08PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-04SEC
2026-08-28CORRESPSEC
2026-08-28S-1/ASEC
2026-08-26UPLOADUpload SubmissionSEC
2026-08-20S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-1410-Q/A2026-03-31SEC
2026-08-148-KCurrent report2026-08-10SEC
2026-08-06DNotice of sales of securities on Form D (Regulation D)SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-16POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-07-018-KCurrent report2026-07-01SEC
2026-06-308-KCurrent report2026-06-29SEC
2026-06-268-KCurrent report2026-06-24SEC
2026-06-18EFFECTEffectiveness filing by commission orderSEC
2026-06-18S-1/ASEC
2026-06-16CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-0799.99K300
2026-060000
2026-05430.00K300
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC4.65%
CITADEL ADVISORS LLC1.78%
HRT FINANCIAL LP1.21%
VANGUARD FIDUCIARY TRUST CO0.58%
GEODE CAPITAL MANAGEMENT, LLC0.53%
Tower Research Capital LLC0.37%
Connective Capital Management, LLC0.30%
VANGUARD CAPITAL MANAGEMENT LLC0.18%
Golden State Wealth Management, LLC0.07%
CITIGROUP INC0.02%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.51%
VANGUARD EXTENDED MARKET INDEX FUND0.18%
Fidelity Series Total Market Index Fund0.12%
Fidelity Total Market Index Fund0.01%
Fidelity Nasdaq Composite Index Fund0.01%

OakChart. HCWB. Cached 15 minutes.

Some panels did not load: ratings.